Small team, big need Panorama Medicine is a small, VC-backed startup focused on RNA splicing therapeutics, presenting a potential market for specialized biotech software, services, and collaboration opportunities with larger pharma companies seeking innovative computational biology and drug discovery capabilities.

RNA splicing focus The company’s PAN platform targets RNA defects and splicing events, signaling a sales angle for partnerships around genomics data, splicing analytics, assay development, and screening modalities to accelerate preclinical programs.

Funding and leadership With recent leadership appointments and a total funding of $8.7M, Panorama may be receptive to strategic alliances, co-development deals, and investor-backed partnerships to scale technology and expand pipeline opportunities.

Early revenue profile Revenue is under one million dollars, indicating a growth-stage company open to out-licensing, milestone-based collaborations, or contract research services to monetize PAN capabilities while expanding its platform.

Collaborative potential The company emphasizes collaboration with the global drug development community, presenting a clear opportunity for partnership, licensing, or joint venture proposals with biotechs and pharma players seeking RNA-targeted therapeutics and advanced computational tools.